Chronic lymphocytic leukemia (CLL) treatment options depend on your diagnosis. In earlier stages, “watchful waiting” may be recommended. More advanced CLL may require a combination of therapies.
Cyprus Mail on MSN
Sequoia zanubrutinib study: Long-term insights into BTK inhibition in treatment-naïve CLL/SLL
IntroductionBruton’s tyrosine kinase (BTK) is at the core of present day treatment in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) which in turn is redefining first line and ...
Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...
Six-year Sequoia data show zanubrutinib in frontline CLL extends PFS far beyond bendamustine‑rituximab, delaying next ...
In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how clinicians can communicate effectively and ...
In part 2 of his recent interview with The American Journal of Managed Care ®, Adam Kittai, MD, addressed how he counsels ...
Propensity-matched TriNetX cohorts of ibrutinib and acalabrutinib recipients showed atrial fibrillation incidence rising with ...
Opportunities include identifying strategic regions for clinical trials, understanding enrollment trends, and analyzing trial success rates. The report aids investment strategies, saving time and cost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results